CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Stribild +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02251236
NCT02251236N/ACompleted
CompareCT.gov

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

University of California, San Diego·interventional·Posted Sep 29, 2014·Updated Oct 31, 2019

In Brief

A clinical study evaluating Stribild and Genvoya for HIV. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen\* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR\*\* (if available) for 24 weeks. \*Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. \*\*Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsGilead Sciences, University at Buffalo

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 29, 2014
Enrollment StartJan 1, 2016
Primary CompletionJan 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 11.8 years ago

Interventions

Stribilddrug

To be administered orally, once daily with food.

Genvoyadrug

To be administered orally, once daily with food.